Studies suggest that approximately 50% of men who have been diagnosed with local prostate cancer will get metastatic cancer during their lifetime. Metastatic prostate cancer also called advanced prostate cancer occurs when cancer cells from the prostate gland spread to other body parts. This cancer can spread to lymph nodes outside the pelvis, bones, or other organs like the liver or lungs. This cancer is considered stage IV prostate cancer. Metastatic prostate cancer clinical trials are discovering new and innovative treatments. These studies test new metastatic prostate cancer therapeutics and treatment strategies offering patients access to novel therapies.
The Metastatic Prostate Cancer Pipeline Report by Expert Market Research gives comprehensive insights into metastatic prostate cancer disease emerging drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for metastatic prostate cancer. The metastatic prostate cancer pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from metastatic prostate cancer.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing metastatic prostate cancer pipeline development activities are covered in the report.
Metastatic prostate cancer, which is also called advanced prostate cancer is the spread of tumor cells from the prostate to other body parts, including lymph nodes or bones. It can also spread to organs such as the liver and lungs. The rare locations to which metastasis prostate cancer can spread include adrenal glands, breasts, kidneys, muscles, pancreas, brain, salivary glands, and others. Cancer cells break away from the original tumor and go to lymph vessels and may move through the body.
Treatment for metastatic prostate cancer depends on the stage of the cancer and includes hormone therapy, chemotherapy, radiotherapy, targeted drugs, radioisotope therapy, and steroids among others. Androgen deprivation therapy (ADT) is a type of hormone therapy. The therapy includes taking metastatic prostate cancer drugs to lower levels of androgens or may include surgery to remove the testicles, as they often fuel the growth of prostate cancer cells.
Several companies and institutes are developing innovative metastatic prostate cancer drug candidates to manage the condition. For instance, Curium US LLC is currently doing a phase III trial of Abiraterone with Prednisone or Enzalutamide. The study is being conducted to evaluate the safety and efficacy of 177Lu-PSMA-I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer. Drugs like olaparib and rucaparib target cancer cells with BRCA1 or BRCA2 mutations are also the areas of research. The development of innovative treatments has impacted the pipeline landscape significantly.
This section of the report covers the analysis of metastatic prostate cancer drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s metastatic prostate cancer therapeutic assessment covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s metastatic prostate cancer clinical assessment covers 50+ drug analyses based on the route of administration.
The metastatic prostate cancer report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for metastatic prostate cancer pipeline drugs, having 800+ drugs in phase II.
The drug molecules categories covered under metastatic prostate cancer pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. According to a phase II study conducted by Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy, a monoclonal antibody called enoblituzumab, is safe in men with aggressive prostate cancer and induces clinical activity against cancer throughout the body. It will be the first promising antibody-based immunotherapy agent to treat prostate cancer, if confirmed in additional studies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for metastatic prostate cancer.
The EMR metastatic prostate cancer report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in metastatic prostate cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and metastatic prostate cancer therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming metastatic prostate cancer drug candidates.
The trial is designed to evaluate the overall survival improvement with aflibercept compared to placebo in patients who are receiving prednisone for metastatic androgen-independent prostate cancer. The trial is sponsored by Sanofi and is currently under phase III.
The objective of the study is to demonstrate the success of carboplatin in patients with advanced metastatic castration-resistant prostate cancer and DNA repair defects. The trial is sponsored by Aurelius Omlin and is currently under phase II.
Bayer is developing this metastatic prostate cancer drug candidate and is currently under phase III. The study is being conducted to evaluate the safety and efficacy of multiple doses of Ra-223 dichloride in patients with CRPC metastatic to the bone.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Metastatic Prostate Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for metastatic prostate cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within metastatic prostate cancer pipeline insight.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share